
ADC Therapeutics Realigns Strategy After Regulatory Setbacks
ADC Therapeutics reported $18.6 million in second-quarter product revenue as the company navigates a challenging regulatory landscape for its cancer drug, ZYNLONTA. Following a critical pre-supplemental Biologics License Application meeting with the FDA regarding its LOTIS-5 trial, the firm is now re-evaluating its regulatory path to full approval.























